




COVID-19 Provider Update

Wednesday, April 6, 2022


First Dose of COVID-19 Vaccine Administered by Week and Age Group

Data reported to CT Wiz by 3/29/2022



Additional Dose of COVID-19 Vaccine Administered by Week and Age Group





Data reported to CT Wiz by 3/29/2022





Percent with at least one dose of COVID-19 vaccine by Race / Ethnicity and Age Group

Data reported to CT Wiz by 3/29/2022




Race — Hispanic — NH Black — NH White



Percent with an additional dose of COVID-19 vaccine by Race / Ethnicity and Age Group

Data reported to CT Wiz by 3/29/2022



Additional Booster Dose Recommendations

The CDC updated the [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) currently authorized or approved in the United States to reflect the recommendation of a second booster dose for specific populations. See the published language relating to second booster dose recommendations below:

- People ages 12 years and older who are [moderately or severely immunocompromised](#) **may** choose to receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
- Adults ages 50 years and older who are not moderately or severely immunocompromised **may** choose to receive a [second booster dose](#) using an mRNA COVID-19 vaccine at least 4 months after the first booster dose.
- People ages 18–49 years who are not moderately or severely immunocompromised and who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose **may** receive a second booster dose using an mRNA COVID-19 vaccine at least 4 months after the first Janssen booster dose.

FDA VRBPAC [meeting](#) scheduled for April 6th to discuss considerations for use of COVID-19 vaccine booster doses and the process for COVID-19 vaccine strain selection to address current and emerging variants. No votes are expected.

Vaccine Schedule for Individuals who are NOT Immunocompromised

Vaccine	0 month	1 month	2 month	3 month	4 month	5 month	6 month	7 month	8 month	9 month	10 month	11 month
Pfizer-BioNTech (ages 5–11 years)	1 st dose	2 nd dose (3 weeks after 1 st dose)										
Pfizer-BioNTech (ages 12 years and older)	1 st dose	2 nd dose† (3–8 weeks after 1 st dose)					Booster dose† (at least 5 months after 2 nd dose)				See footnote§	
Moderna (ages 18 years and older)	1 st dose	2 nd dose† (4–8 weeks after 1 st dose)					Booster dose† (at least 5 months after 2 nd dose)				See footnote§	
Janssen (ages 18 years and older)	1 st dose		Booster dose† (at least 2 months after 1 st dose)				See footnote§					

§ People ages 18–49 years who received Janssen COVID-19 Vaccine as both their primary series dose and booster dose may receive an mRNA COVID-19 booster dose at least 4 months after the Janssen booster dose. People ages 50 years and older may choose to receive a second booster dose if it has been at least 4 months after the first booster dose.

Vaccine Schedule for Individuals who ARE Immunocompromised

Vaccine	0 month	1 month	2 month	3 month	4 month	5 month	6 month	7 month	8 month	9 month
Pfizer-BioNTech (ages 5–11 years)	1 st dose	2 nd dose (3 weeks after 1 st dose)	3 rd dose (at least 4 weeks after 2 nd dose)							
Pfizer-BioNTech (ages 12 years and older)	1 st dose	2 nd dose (3 weeks after 1 st dose)	3 rd dose (at least 4 weeks after 2 nd dose)			Booster dose* (at least 3 months after 3 rd dose)				See footnote [‡]
Moderna (ages 18 years and older)	1 st dose	2 nd dose (4 weeks after 1 st dose)	3 rd dose (at least 4 weeks after 2 nd dose)			Booster dose* (at least 3 months after 3 rd dose)				See footnote [‡]
Janssen (ages 18 years and older)	1 st dose	2 nd (additional) dose [†] using an mRNA COVID-19 vaccine (at least 4 weeks after 1 st dose)			Booster dose* (at least 2 months after additional dose)			See footnote [‡]		

[‡]People ages 12 years and older may choose to receive a second booster dose using an mRNA COVID-19 vaccine if it has been at least 4 months after the first booster dose. For people ages 12–17 years, only Pfizer-BioNTech can be used.

Additional Moderna Product Presentation Approved

The Moderna Emergency Use Authorization (EUA) was recently updated to reflect the availability of a new [booster dose presentation](#). While the dose volume differs, this presentation contains the same ingredients and is the same strain formulation as the currently available product. The new product is a 50ug dose presented as a 5-dose multi-dose vial with a dark blue cap and purple border and is 0.5 mL injection volume. This presentation is indicated for booster dose use only and is not approved or indicated for use as a primary dose in the Moderna series.

This product is not yet available for order.

Additional information regarding availability will be distributed as it becomes available.

Additional Product Update:

Beginning on Monday, April 11, 2022, Moderna COVID-19 vaccine shipments will now come with **one ancillary kit** (1 ancillary kit to 1 carton of vaccine, instead of 2 ancillary kits to 1 carton of vaccine).

Holiday Deliveries

	Friday, APRIL 15	Saturday, APRIL 16	Sunday, APRIL 17	Monday, APRIL 18
Pfizer	Deliveries*	No Deliveries	No Deliveries	Deliveries
Moderna/ Janssen	Deliveries*	No Deliveries	No Deliveries	No Deliveries

Please account for any holiday closures when placing orders for vaccine next week.

CDC Morbidity and Mortality Weekly Report



**Stay informed
about COVID-19**

Read the latest
reports from
MMWR




bit.ly/MMWR_COVID19

MMWR

Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COVS.2 (Janssen [Johnson & Johnson]) Vaccine Dose Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults — VISION Network, 10 States, December 2021–March 2022

VE against COVID-19–associated emergency department/urgent care visits was 24% after 1 Jansen dose, 54% after 2 Jansen doses, and 79% after 1 Jansen/1 mRNA dose, compared to 83% after 3 mRNA doses. VE for the same strategies against COVID-19–associated hospitalization was 31%, 67%, 78%, and 90% respectively. All eligible persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19. Adult Janssen primary vaccine recipients should preferentially receive a heterologous mRNA vaccine booster dose ≥ 2 months later.

CDC Morbidity and Mortality Weekly Report



Cardiac Complications After SARS-CoV-2 Infection and mRNA COVID-19 Vaccination — PCORnet, United States, January 2021–January 2022



CT WiZ/VAMS Update

Transferring COVID-19 Vaccines to Other Clinics


Tips for Running CT WiZ Reports

Transferring COVID-19 Vaccines to Other Clinics not using CT WiZ for Inventory Management

• COVID-19 Vaccine Transfer Form (DPH)

Please complete and email this form to DPH whenever transferring COVID-19 vaccines between CoVP enrolled providers. You must have also completed and emailed this Supplemental COVID-19 Redistribution Agreement (CDC) to DPH at DPH.Immunizations@ct.gov

• The Ancillary Redistribution Gadget for Healthcare (ARGH) Tool is a tool that assists providers who are redistributing vaccines to other CoVP Clinics to identify the number of ancillary kit items needed to pack based on the number of requested doses.



Connecticut COVID-19 Vaccine Program
COVID-19 Transfer Form
Completed forms can be e-mailed to:
DPH.Immunizations@CT.Gov

Click here to email this form to DPH

Transferring/Redistributing Pfizer Vaccine:

- Recommended transport in the original shipper or in an approved unit
- Transported at refrigerated temperatures according to existing CDC
- Transport in original carton when possible
- Do not transfer vials more than once.
- For more information, please visit [Pfizer's webpage](#)

Transferring/Redistributing Moderna Vaccine:

- Recommended transport in the frozen state
- Limit transport in the liquid state. If liquid transport is required, follow precautions:
- Transport in original carton when possible
- Carton should be placed with padding material (e.g., bubble product/carton movement)
- Do not transfer vials more than once.
- For more information, please visit [Moderna's webpage](#)

Receiving Transferred/Redistributed Vaccine:

- Upon arrival of vaccine, check the quantities and lot numbers against what
- Sign and date the bottom of the form in the appropriate place (Signature of
- Submit completed form to DPH.Immunizations@CT.Gov

CDC Supplemental COVID-19 Vaccine Redistribution Agreement

The Centers for Disease Control and Prevention (CDC) plans to ship a minimum order size of COVID-19 vaccine, constituent products, and ancillary supplies at no cost directly to enrolled COVID-19 vaccination providers throughout the United States. The federally contracted vaccine distributor uses validated shipping procedures to maintain the vaccine cold chain and minimize the likelihood of vaccine loss or damage during shipment. There may be circumstances where COVID-19 vaccine needs to be redistributed beyond the identified primary CDC ship-to sites (i.e., for orders smaller than the minimum order size or for large organizations whose vaccine is shipped to a central depot and requires redistribution to additional clinic locations). In these instances, vaccination provider organizations/facilities, third-party vendors, and other vaccination providers may be allowed to redistribute vaccine, if approved by the jurisdiction's immunization program and if validated cold chain procedures are in place in accordance with the manufacturer's instructions

and CDC's guidance on COVID-19 vaccine storage and handling. There must be a signed *CDC Supplemental COVID-19 Vaccine Redistribution Agreement* for the facility/organization conducting redistribution and a fully completed *CDC COVID-19 Vaccination Provider Profile Information form* (Section B of the CDC COVID-19 Vaccination Program Provider Agreement) for each receiving vaccination location.

The parties to this agreement are CDC and healthcare organizations, third-party vendors, and vaccination providers that redistribute COVID-19 vaccine. CDC cannot reimburse costs of redistribution beyond the initial designated primary CDC ship-to site(s), or for purchase of any vaccine-specific refrigerators or qualified containers. Therefore, organizations planning for redistribution of COVID-19 vaccine must carefully assess the associated risks and costs (e.g., vaccine loss due to temperature excursions, purchase of vaccine-specific portable refrigerators and/or containers) before planning this activity.

Organization Information

Organization/facility name:

FOR OFFICIAL USE ONLY VTrckSID:

Unique COVID-19 Organization ID (from Section A):

Primary address and contact information of COVID-19 vaccination organization

Street address 1: Street address 2:

Transferring Provider Facility Name: **Date:**

Address: **Phone:**

City: **Person Contact:**

Receiving Provider Facility Name: **Date:**

Address: **Phone:**

City: **Person Contact:**

Instructions:

- This tool identifies the no. of ancillary items required to pick/pack given a required no. of doses
- For each kit being broken down, please enter the required number of doses in the yellow box
- Please note, figures are rounded for ease of use. This means for low-dose quantities, recommended items may not include low volume items such as Needle Info Cards, Face Shields or Surgical Masks

Moderna 100 Adult			Moderna 140 Adult		
Product	Product Description	Qty	Product	Product Description	Qty
Needles	22-25G x 1"	85	Needles	1"	54
Needles	22-25G x 1.5"	20	Syringes	1ml or 3ml LDV	54
Syringes	1ml	105	Needles	22-25G x 1"	36
Alcohol Pads	Sterile, individually sealed	210	Syringes	1ml or 3ml	36
Vaccination Card		100	Needles	22-25G x 1.5"	18
Needle Info Card		1	Syringes	1ml or 3ml	18
Face Shield		2	Alcohol Pads	Sterile, individually	214
Surgical Mask		4	Vaccination Card		107
			Needle Info Card		1
			Face Shield		2
			Surgical Mask		4

Before transferring


Signature of Transferor:

Signature of Receiver:

Moderna ancillary kit tool | **Pfizer ancillary kit tool** | **Janssen ancillary kit tool**


Transfer COVID-19 Vaccines in CT WiZ

- Transfer screen within the On-Hand Inventory screen allows you to [transfer vaccines](#) to another clinic and receive vaccines from another clinic.
- Both clinics must be set up in CT WiZ for inventory management.
- Prior to transferring vaccines with another clinic, confirm whether they are using CT WiZ for their Inventory Management.




It's Your Best Shot!
CT WiZ
Connecticut
Immunization Information System

How do I transfer and receive vaccines?



Connecticut Department of Public Health
Keeping Connecticut Healthy



Use this tool to complete the steps to transfer vaccines between clinics

[Transfers-Quick-Guide.pdf \(ct.gov\)](#)


Transfers

For inventory transfers, when contacting the provider, you must find out if the clinic you're transferring with is currently using CT WiZ for inventory management. Depending on this answer, you will have to enter a transfer two different ways.

	Both clinics on CT WiZ	Transferring clinic not on CT WiZ Receiving clinic on CT WiZ
Transfer In	<ul style="list-style-type: none"> Go to your vaccines On Hand screen Click on blue pending transfer hyperlink at top of page Click Received next to vaccine transferred in Enter the Date and Time Click Ok Repeat for each vaccine transferred in 	<ul style="list-style-type: none"> Go to your vaccines On Hand screen Click on Add New Inventory at the top of the screen Enter the Date and Time Select the Inventory location where vaccines are going Choose the correct vaccine and NDC code Carefully type in Lot Number and Expiration Date Funding Source will be Blended Public CVP for CVP vaccines, and Pandemic for COVID-19 vaccines Enter the number of doses transferred in under Doses Adjusted In the Comments, write the name of the clinic or pin the vaccines are being transferred in from Click Create Repeat for all vaccines transferred in
Transfer Out	<ul style="list-style-type: none"> Go to your vaccines On Hand screen Select the vaccine and click Action, Transfer Enter the Date and Time Select the Destination Inventory Location (Organization-Pin-Unit) Enter the number of Doses Transferred Click Create A blue pending transfer hyperlink will appear on the top of your inventory screen showing the pending transfer. Once your transfer is accepted by the other clinic, this will disappear 	<ul style="list-style-type: none"> Go to your vaccines On Hand screen Select the vaccine you are transferring out and click Action, Adjustment Enter the Date and Time For Reason choose CVP-Transfer to offline clinic Modification will default to subtract Enter the amount of doses you are transferring under Doses Adjusted In the Comments field, write the name or pin number of the clinic you are transferring to Click Create Repeat for all vaccines transferred
	No paper transfer form!	A paper form still needs to be sent to DPH




Training Materials for CT WiZ Reports



How to Run a Reminder/Recall

CT WiZ Reports Manual –
see page 55 for COVID-19
Series Report



Tips for Running CT WiZ Reports

Visit: [Patient Management](#) for CT WiZ Training

- If patient leaves your clinic, [inactivate patients in CT WiZ](#) – *before* you run reports.
- **Run smaller Reports** – they are easier to manage.
 - Larger reports will slow the CT WiZ system down and your report may timeout.
- Reminder/Recall Report generates overnight.
- Multiple reports can be generated to cover all patients (stagger over different days).
- Use the dose box by the vaccine/s to help target the data you are looking to generate.
- For help: [Contact Us](#)

Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting <https://dph-cthelpdesk.ct.gov/Ticket>



Appendix



Age coverage: Specific age groups

Reported to CT WiZ by 3/29/2022

AD
Updated 3/31
Data as of 3/29

Age Range	% of Population	CT Population	At least one dose		Fully vaccinated		Additional dose received	
			Number	%	Number	%	Number	%
<5	5.00%	181,710	0	0.00%	0	0.00%	0	0.00%
5-11	8.00%	277,630	133,340	48.0%	115,452	41.6%	627	0.2%
12-15	5.00%	176,600	143,416	81.2%	130,886	74.1%	41,354	23.4%
16-17	3.00%	91,500	80,428	87.9%	73,482	80.3%	31,173	34.1%
18-24	10.00%	342,073	290,139	84.8%	241,571	70.6%	100,560	29.4%
25-34	13.00%	448,029	400,629	89.4%	345,945	77.2%	146,920	32.8%
35-44	12.00%	427,141	400,421	93.7%	355,587	83.2%	178,563	41.8%
45-54	13.00%	476,905	432,342	90.7%	395,133	82.9%	229,626	48.1%
55-64	14.00%	513,455	505,477	98.4%	466,666	90.9%	310,474	60.5%
65-74	10.00%	352,819	368,267	100.0%	337,837	95.8%	256,230	72.6%
75-84	5.00%	186,095	192,118	100.0%	175,614	94.4%	132,919	71.4%
85+	3.00%	91,330	80,149	87.8%	72,526	79.4%	48,730	53.4%
Grand Total		3,565,287	3,026,726	84.9%	2,710,699	76.0%	1,477,176	41.4%

At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J

Fully vaccinated includes individuals who received one dose of J&J, two doses of an mRNA vaccine (Pfizer or Moderna)

Additional dose received includes individuals who have had at least one dose after completion of the primary COVID-19 vaccine series (mRNA or J & J)

Total excludes 421 people with unknown age



Age coverage: Everyone over a certain age

Data reported to CT Wiz by 3/29/2022

Age Range	% of Population	CT Population	At least one dose		Fully vaccinated		Additional dose received	
			Number	%	Number	%	Number	%
All ages	100.00%	3,565,287	3,027,156	84.9%	2,711,040	76.0%	1,477,296	41.4%
5+	95.00%	3,383,577	3,026,726	89.5%	2,710,699	80.1%	1,477,176	43.7%
12+	87.00%	3,105,947	2,893,386	93.2%	2,595,247	83.6%	1,476,549	47.5%
16+	82.00%	2,929,347	2,749,970	93.9%	2,464,361	84.1%	1,435,195	49.0%
18+	80.00%	2,837,847	2,669,542	94.1%	2,390,879	84.2%	1,404,022	49.5%
35+	57.00%	2,047,745	1,978,774	96.6%	1,803,363	88.1%	1,156,542	56.5%
45+	45.00%	1,620,604	1,578,353	97.4%	1,447,776	89.3%	977,979	60.3%
55+	32.00%	1,143,699	1,146,011	100.2%	1,052,643	92.0%	748,353	65.4%
65+	18.00%	630,244	640,534	100.0%	585,977	93.0%	437,879	69.5%
75+	8.00%	277,425	272,267	98.1%	248,140	89.4%	181,649	65.5%

At least one dose includes individuals who have received one dose of Pfizer, Moderna, or J&J
Fully vaccinated includes individuals who received one dose of J&J, two doses of an mRNA vaccine (Pfizer or Moderna)
Additional dose received includes individuals who have had at least one dose after completion of the primary COVID-19 vaccine series (mRNA or J & J)